The Dance Before the Drug: Hatch-Waxman, the Orange Book, Biosimilars, and Litigation on a Statutory Clock
By Casey Scott McKay ·
Life sciences patent litigation runs on a statutory timetable that most patent practitioners never encounter, and the timetable drives the strategy more than the patents do. This article explains the abbreviated approval pathway, what an Orange Book listing does, and why a paragraph IV certification is an artificial act of infringement that manufactures jurisdiction before any product exists. It works the thirty-month stay, first-applicant exclusivity, and the research safe harbor that makes the whole system possible. It covers the section viii carve-out and the induced infringement exposure a skinny label creates, then turns to the parallel biologics regime and its very different information-exchange procedure. It closes with at-risk launch analysis, settlement structures and the antitrust scrutiny they attract, and what a launch risk assessment should actually contain.
IP and Technology > Patent Litigation | Article | Published 9 October 2023 - Updated 16 May 2025 | Casey Scott McKay - marksy.us
Summary. Life sciences patent litigation runs on a statutory timetable that most patent practitioners never encounter, and the timetable drives the strategy more than the patents do. This article explains the abbreviated approval pathway, what an Orange Book listing does, and why a paragraph IV certification is an artificial act of infringement that manufactures jurisdiction before any product exists. It works the thirty-month stay, first-applicant exclusivity, and the research safe harbor that makes the whole system possible. It covers the section viii carve-out and the induced infringement exposure a skinny label creates, then turns to the parallel biologics regime and its very different information-exchange procedure. It closes with at-risk launch analysis, settlement structures and the antitrust scrutiny they attract, and what a launch risk assessment should actually contain.
Keywords: Hatch-Waxman · abbreviated new drug application · Orange Book listing · paragraph IV certification · artificial act of infringement · thirty month stay · first applicant exclusivity · safe harbor research exemption · section viii carve-out · skinny label · induced infringement · biosimilar · BPCIA patent dance · purple book · declaratory judgment · at-risk launch · regulatory exclusivity · settlement and antitrust scrutiny · listing challenges · launch risk assessment
This is premium Marksy content — the full document is available to subscribers.